Permanent Relief from Intermittent Cold Stress-Induced Fibromyalgia-Like Abnormal Pain by Repeated Intrathecal Administration of Antidepressants by Michiko Nishiyori et al.
RESEARCH Open Access
Permanent relief from intermittent cold stress-
induced fibromyalgia-like abnormal pain by
repeated intrathecal administration of
antidepressants
Michiko Nishiyori1, Hitoshi Uchida1, Jun Nagai1, Kohei Araki1, Takehiro Mukae1, Shiroh Kishioka2 and Hiroshi Ueda1*
Abstract
Background: Fibromyalgia (FM) is characterized by chronic widespread pain, which is often refractory to
conventional painkillers. Numerous clinical studies have demonstrated that antidepressants are effective in treating
FM pain. We previously established a mouse model of FM-like pain, induced by intermittent cold stress (ICS).
Results: In this study, we find that ICS exposure causes a transient increase in plasma corticosterone concentration,
but not in anxiety or depression-like behaviors. A single intrathecal injection of an antidepressant, such as
milnacipran, amitriptyline, mianserin or paroxetine, had an acute analgesic effect on ICS-induced thermal
hyperalgesia at post-stress day 1 in a dose-dependent manner. In addition, repeated daily antidepressant
treatments during post-stress days 1-5 gradually reversed the reduction in thermal pain threshold, and this
recovery was maintained for at least 7 days after the final treatment. In addition, relief from mechanical allodynia,
induced by ICS exposure, was also observed at day 9 after the cessation of antidepressant treatment. In contrast,
the intravenous administration of these antidepressants at conventional doses failed to provide relief.
Conclusions: These results suggest that the repetitive intrathecal administration of antidepressants permanently
cures ICS-induced FM pain in mice.
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2. Background
Fibromyalgia (FM) is characterized by generalized ten-
derness and chronic widespread pain that affects 2-4% of
the population in industrialized nations and primarily
affects females [1]. Although its etiology and pathogen-
esis are largely unknown, emerging evidence indicates
that pain amplification within the central nervous system
(CNS) plays a critical role in the pathology of FM pain
[2]. Recent studies, including functional imaging, have
revealed that this central amplification process depends,
in part, on deficits in endogenous descending pain inhibi-
tory pathways [3,4] and abnormal pain processing [5]. In
addition, FM pain is often refractory to treatment using
conventional painkillers, such as non-steroidal anti-
inflammatory drugs and opioids [6]. However, numerous
studies have demonstrated the effectiveness of antide-
pressants and antiepileptics, such as gabapentin and
pregabalin, in the treatment of FM pain [7,8].
There are several animal models of FM pain, induced
by either intramuscular injection of acidic saline [9],
vagotomy [10], sound stress [11] or depletion of bio-
genic amines [12]. However, in order to better under-
stand the molecular basis of the underlying pain
mechanisms, it is necessary to establish an animal
model which accurately reflects the pathological and
pharmacotherapeutic features of the disease.
Recently, we established a mouse model of FM using
intermittent cold stress (ICS), which produces long-last-
ing thermal hyperalgesia and mechanical allodynia, pre-
dominantly in females [13]. We found that gabapentin,
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particularly when injected intracerebroventricularly, had
potent anti-hyperalgesic and anti-allodynic effects in this
model [13]. In addition, systemically and intracerebro-
ventricularly-administered morphine was found to have
no analgesic effect in ICS-exposed mice, due to a failure
to activate descending pain inhibitory pathways [14].
These findings indicate that our ICS model might accu-
rately reflect the pathological and pharmacotherapeutic
features of FM pain. In this study, we examine whether
various antidepressants can ameliorate the abnormal
pain sensations in this model.
3. Materials and methods
3.1. Animals
Male C57BL/6J mice weighing 18-22 g were used. They
were kept in a room with an ambient temperature of 21
± 2°C, with free access to a standard laboratory diet and
tap water. All procedures were approved by the Naga-
saki University Animal Care Committee and complied
with the recommendations of the International Associa-
tion for the Study of Pain [15].
3.2. Drug treatments
Antidepressants were obtained from Sigma (St. Louis,
MO, USA). Milnacipran, paroxetine, and amitriptyline
were dissolved in artificial cerebrospinal fluid (aCSF; 125
mM NaCl, 3.8 mM KCl, 2.0 mM CaCl2, 1.0 mM MgCl2,
1.2 mM KH2PO4, 26 mM NaHCO3, 10 mM glucose, pH
7.4). Mianserin was dissolved in physiological saline. For
vehicle treatments, aCSF or saline was injected. Intrathecal
(i.t.) injections were administered according to Hylden and
Wilcox [16] using a 30-gauge needle. The site of injection
was chosen to be between spinal L5 and L6–near where
the spinal cord ends and the cauda equina begins. This
allowed us to maximize inter-vertebral accessibility and to
minimize the possibility of spinal damage. After sufficient
training, the experimenters were able to perform the tech-
nique without causing injury to the animals.
3.3. Experimental model of fibromyalgia
ICS exposure and constant cold stress (CCS) were per-
formed as previously reported [13]. Briefly, for the ICS
model, mice were placed on stainless mesh plate in a
cold room at 4°C overnight (from 4:30 pm to 10:00 am),
followed by ICS with environmental temperatures alter-
nating between 24 and 4°C every 30 min, from 10:00 am
to 4:30 pm. These procedures were repeated twice. On
day 3, the mice were adapted to 24°C for 1 h before beha-
vior testing. We designated day 3 following the onset of
stress exposure as day 1 post-stress exposure (P1). For
the CCS model, mice were placed in the cold room from
4:30 pm on day 1 to 10:00 am on day 3, followed by
adaptation at 24°C for 1 h. Mice in the control group
were kept at 24°C for all 3 days (from 4:30 pm on day 1
to 10:00 am on day 3). During the stress period, two mice
were kept in each cage (12 × 15 × 10.5 cm), with free
access to food and agar as alternate drink water in place
of fluid. Although the body weight of mice was decreased
during and after the ICS stress, it attained to the control
mice level as early as 4 day after the stress (Figure 1).
3.4. Measurement of plasma corticosterone
Plasma corticosterone levels were measured as described
previously [17]. Briefly, plasma was separated by centri-
fugation at 3 000 g for 15 min at 4°C and collected into
ice-chilled tubes containing 0.1% EDTA and stored at
-80°C until use. Blood samples were collected at 9:00
pm in order to exclude the effect of circadian rhythms
on circulating plasma corticosterone. The plasma corti-
costerone level was estimated fluorometrically, according
to the method of Zenker and Bernstein [18].
3.5. Assessment of stress-related behaviors
Spontaneous locomotor activity was measured in the
open filed (22 × 33 cm) for 3 min, using SCANET appa-
ratus (Melquest, Japan). In the elevated plus-maze test
used to estimate anxiety, the time spent in the open
arm was recorded during a 6-min period. To assess
depression-like behaviors, the tail-suspension test was
performed [19,20]. Mice were suspended 30 cm above
the floor using adhesive tape, and the total duration of
immobility during a 6-min period was measured.
3.6. Nociception tests
In the thermal paw withdrawal test, the nociception
threshold was assessed using the latency of paw
Figure 1 Changes in body weight in ICS treated mice. Results
represent the percentage of body weight of mice, compared to the
value at 1 day before ICS stress (Pre). *p < 0.05, vs. control group.
Data are the means ± S.E.M; 6 mice per group.
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withdrawal upon a thermal stimulus [21,22]. Unanesthe-
tized animals were placed in plexiglass cage on top of a
glass sheet and acclimated for 1 h. A thermal stimulator
(IITC Inc., Woodland Hills, CA, USA) was positioned
under the glass sheet and the focus of the projection
bulb was aimed exactly at the middle of the plantar sur-
face of the animal. A mirror attached to the stimulator
permitted visualization of the plantar surface. A cut-off
time of 20 s was set to prevent tissue damage.
The mechanical paw pressure test was performed as
described previously [22]. Briefly, mice were placed in a
plexiglass chamber on a 6 × 6 mm wire mesh grid floor
and allowed to acclimate for a period of 1 h. A mechan-
ical stimulus was then delivered to the middle of the
plantar surface of the right-hind paw using a Transducer
Indicator (Model 1601; IITC Inc., Woodland Hills, CA,
USA). The pressure needed to induce a flexor response
was defined as the pain threshold. A cut-off pressure of
20 g was set to avoid tissue damage. In these experi-
ments using thermal and mechanical tests, the thresh-
olds were determined from three repeated challenges at
10 min intervals, and the averages were used for statisti-
cal analysis. For the time-course experiments, we mea-
sured the paw-withdrawal latencies (PWL) at 30, 60,
and 180 min after intrathecal injection of antidepressant.
In the area under the curve (AUC) analysis of antide-
pressant-induced analgesia, we calculated the AUC gen-
erated by plotting analgesic threshold (after deducting
the control threshold from each threshold point) against
time, from 30 to 180 min after antidepressant treatment,
using a trapezoidal method.
3.7. Statistical analysis
In Figure 2 and Table 1, data were analyzed using Stu-
dent’s t-test. In Figures 1, 3, 4, 5 and 6, Tables 2 and 3,
the differences between multiple groups were analyzed
using a one-way ANOVA with the Tukey-Kramer multi-
ple comparison post-hoc analysis. Significance was set at
p < 0.05. All results are expressed as means ± S.E.M.
4. Results
4.1. Effects of ICS stress exposure on plasma
corticosterone levels and anxiety and depression-like
behaviors
We previously designed an improved mouse model for
dysautonomia, also referred to as the specific alternation
of rhythm in temperature (SART) model [23], and
found that ICS, but not CCS, caused long-lasting abnor-
mal pain sensations [13]. In the present study, we used
plasma corticosterone levels as a biomarker for stress.
As shown in Figure 2A, we found that ICS exposure
caused a transient increase in plasma corticosterone
levels at P1. In contrast, CCS exposure had no effect on
plasma corticosterone levels between P1 and P12 (Figure
2A). ICS had no effect on spontaneous locomotor activ-
ity at P1 (Figure 2B). Furthermore there was no signifi-
cant change in the duration of time spent in the open
arm in the elevated plus-maze test or in the total dura-
tion of immobility in the tail-suspension test at P1
Figure 2 Effects of stress exposure on plasma corticosterone
levels, spontaneous locomotor activity, and anxiety and
depression-like behaviors. (A) Time-course of plasma
corticosterone levels after ICS or CCS exposure. (B-D) Lack of
changes in spontaneous locomotor activity in the SCANET
apparatus (B), duration of time spent in the open arm of the plus-
maze test (C), and total duration of immobility in the tail suspension
test (D) at P1. *p < 0.05, vs. control group. Data are expressed as the
means ± S.E.M; 3-5 mice per group.
Table 1 Dose-dependent acute analgesic effects of
antidepressants on ICS-induced thermal hyperalgesia
Drug Dose (μg) n AUC
Milnacipran 0.03 4 50.6 ± 21.5
0.1 6 281.9 ± 71.3*
0.3 4 166.2 ± 31.3*
Amitriptyline 5 3 51.1 ± 85.2
15 7 252.6 ± 42.2*
30 3 235.5 ± 64.4*
Mianserin 10 3 144.7 ± 171.5
20 4 527.8 ± 103.2*
Paroxetine 2 3 40.7 ± 62.4
5 7 211.2 ± 38.6*
10 3 251.3 ± 797*
Thermal pain threshold was assessed at P1, using thermal paw withdrawal
tests. Acute anti-hyperalgesic effects of milnacipran, amitriptyline, mianserin,
and paroxetine were evaluated by AUC, as described in Materials and
Methods. *p < 0.05, vs. vehicle-treated control group.
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Figure 3 Antidepressant-induced acute analgesic effects in ICS treated mice. Thermal pain threshold was assessed at P1 after control or ICS
treatment, using the thermal paw withdrawal test. Results represent the time course of thermal paw withdrawal latencies (PWL, in seconds) after
a single intrathecal injection of antidepressants. (A-D) Each data point in [control + vehicle] and [ICS + vehicle] groups is common. *p < 0.05, vs.
vehicle-treated control group; #p < 0.05, vs. vehicle-treated and ICS-exposed groups. Data are expressed as the means ± S.E.M.; 4-8 mice per
group.
Figure 4 Permanent relief from ICS-induced thermal hyperalgesia by repeated intrathecal administration of milnacipran. Intrathecal
injections of milnacipran (0.1 μg) were given once daily at 11:30 a.m. from P1-P5 after assessment of nociceptive thresholds at 11:00 a.m. Results
represent the basal threshold as the latency to paw-withdrawal from thermal stimuli (PWL, in seconds), just before the daily injection of vehicle
or milnacipran. *p < 0.05, vs. vehicle-treated control group; #p < 0.05, vs. vehicle-treated and ICS-exposed groups. Data are expressed as the
means ± S.E.M.;4-8 mice per group.
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(Figures 2C, D). In addition, there were no gross beha-
vioral changes in mice as early as 1 h after the transfer
from 4°C to 24°C room.
4.2. Antidepressant-induced acute analgesic effects on
thermal hyperalgesia in ICS-exposed mice
Previous reports demonstrated that thermal hyperalgesia
is elicited at P1 after ICS exposure and lasts for at least
12 days [13,14]. As shown in Figure 3, the nociceptive
thermal threshold was significantly reduced and stable
throughout experiments for 180 min. A single intrathe-
cal injection of milnacipran (0.1 μg) had no effect on
the nociceptive threshold in control mice (Figure 3A),
but produced significant anti-hyperalgesic effects that
persisted for at least 180 min post-injection at P1 (Fig-
ure 3A). This effect of milnacipran was dose-dependent
in the range of 0.03-0.1 μg, but declined at 0.3 μg
(Table 1). Statistical significance was observed at 0.1 and
0.3 μg. Similar results were observed with other antide-
pressants, such as amitriptyline (5-30 μg), mianserin (10
and 20 μg), and paroxetine (2-10 μg), as shown in Fig-
ures 3B-D and Table 1. However, with 20 μg of mian-
serin, a significant analgesic effect was observed at 60
min in the control mice, and anti-hyperalgesic effects
were observed until 180 min (Figure 3C). Both amitrip-
tyline and paroxetine showed significant anti-hyperalge-
sic effects, but no significance was observed at 180 min
(Figures 3B, D).
4.3. Permanent relief of abnormal pain by repeated
central administration
As the anti-hyperalgesic effect of milnacipran remained
180 min after intrathecal administration at day P1 after
ICS stress (threshold: ~ 7.46 ± 0.2 s), we measured the
nociceptive threshold at 11:00 a.m. on day P2. As seen
in Figure 4, a significant anti-hyperalgesic effect still
remained (threshold: ~ 7.67 ± 0.6 s). The second admin-
istration of milnacipran was performed at 11:30 a.m.
The basal nociceptive threshold at 11:00 a.m. on day P3
further increased to 8.56 ± 0.8 s. The increase in basal
threshold was maintained by daily administration of mil-
nacipran. Complete recovery to the normal pain thresh-
old was observed on P6, the day following the last
administration, and lasted until P12. Similar complete
reversals of hyperalgesia on P5 and P12 were observed
after 5-day administrations of amitriptyline (15 μg),
mianserin (20 μg), and paroxetine (5 μg), as seen in
Table 2. Complete recovery was also observed with ICS-
induced mechanical allodynia, even on P14, following a
5-day administration of the antidepressants (Figure 5).
4.4. Lack of beneficial effects by repeated systemic
administration
When milnacipran was given by intravenous (i.v.) injec-
tion (10 mg/kg), there was a significant analgesic effect
in the thermal nociception test at 30 min in control
mice. However, there was no significant suppression in
the ICS mouse model using this dose of antidepressant
up to 180 min on P1 (Figure 6A). The absence of an
ameliorative effect on ICS-induced hyperalgesia was also
observed with amitriptyline (3 mg/kg, i.v.), mianserin
(10 mg/kg, i.v.), and paroxetine (1 mg/kg, i.v.), despite
producing significant acute analgesia at 30 min in con-
trol mice (Figures 6B-D). In addition, the repeated sys-
temic administration of milnacipran for 5 days did not
affect the basal threshold throughout the experiment
(Figure 6E). Repeated administrations of amitriptyline,
mianserin or paroxetine also did not provide relief from
ICS-induced hyperalgesia (Table 3).
5. Discussion
Patients with FM exhibit widespread pain, with diverse
symptoms, such as fatigue, depression, and sleep distur-
bance. Although the pathogenesis of FM is not clearly
understood, certain biological stressors, such as auto-
nomic nervous system disorder and psychological dis-
tress seem to be closely related to the development of
FM [24]. An important role for such stressors is sup-
ported by studies using animal models in which rats or
mice are subjected to stressors, such as chemical, sound,
or surgery stress, which induce long-lasting abnormal
pain [9-11,25]. Recently, we reported that ICS produces
long-lasting thermal hyperalgesia and mechanical allody-
nia in mice [13,14]. The ICS-induced pain is bilateral
and female-predominant (after gonadectomy) [13],
which are also features found in FM patients [26].
In this study, mice subjected to ICS exhibited a transi-
ent increase in plasma corticosterone levels on P1. In
Figure 5 Complete relief from ICS-induced mechanical
allodynia. Basal mechanical paw-withdrawal threshold (PWT, in
grams) was assessed at P14, using paw pressure tests. Intrathecal
injection of milnacipran (0.1 μg), amitriptyline (15 μg), mianserin (20
μg), or paroxetine (5 μg), was given once daily from P1-P5, as
described in Figure 4. *p < 0.05, vs. vehicle-treated control group; #p
< 0.05, vs. vehicle-treated and ICS-exposed groups. Data are
expressed as the means ± S.E.M.; 3-6 mice per group.
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Figure 6 Lack of anti-hyperalgesic effects by systemic administration of antidepressants. Thermal pain threshold was assessed at P1 after
control or ICS-treatment, using thermal paw withdrawal tests. (A-D) Results represent the time-course of thermal paw-withdrawal latencies (PWL,
in seconds) after a single i.v. injection of antidepressants. (A-D) Each data point in [control + vehicle] and [ICS + vehicle] groups is common. (E)
Milnacipran was given i.v. once daily for 5 days, as described in Figure 4. Results represent the basal threshold as the latency to paw-withdrawal
from thermal stimuli (PWL, in seconds), just before the daily injection of vehicle or milnacipran. *p < 0.05, vs. vehicle-treated control group; #p <
0.05, vs. vehicle-treated and ICS-exposed groups. Data are expressed as the means ± S.E.M.; 3-6 mice per group.
Nishiyori et al. Molecular Pain 2011, 7:69
http://www.molecularpain.com/content/7/1/69
Page 6 of 10
contrast, there was no significant change in corticoster-
one levels in mice subjected to CCS. Considering that
the abnormal pain in CCS mice was only transient, and
not long-lasting [13,14], the rise in corticosterone levels
in ICS mice likely played a role in the appearance of
abnormal pain. A recent report suggests that the stress-
induced increase in corticosterone concentration may be
related to abnormal pain behavior in an FM-like animal
model, possibly through a mechanism involving epi-
nephrine release [27].
In our ICS model, the mice did not show significant
changes in the tail-suspension test, a behavioral test
designed to assess depression-like behavior [28]. This is
in contrast to a study using less frequent temperature
alternation (the SART model), in which mice exhibited
hyperalgesia for only a week [29], and there was a tran-
sient reduction of immobility duration in forced swim-
ming test, followed by gradual recovery in 5-6 days [30].
As the forced swimming causes a facilitation of immobi-
lity in an antidepressant-reversible manner [31], it is not
clear whether the transient reduction of immobility
duration reflects depression. From this point of view,
the tail suspension test seems to be a better method for
evaluation of depression-related despair behavior. Gaba-
pentin and pregabalin are widely used to treat FM
patients in the clinic [32,33]. These medicines alleviate
abnormal pain and the accompanying fatigue and
insomnia, without affecting depressive symptoms
[33,34]. Therefore, the presence of depression-like beha-
vior is unlikely to be necessary in animal models of FM.
Consequently, the ICS model may be more clinically
relevant than the SART model for evaluating long-term
pain.
Various antidepressants have been used for FM in the
clinic [35,36]. Recently milnacipran and duloxetine, ser-
otonin/norepinephrine reuptake inhibitors, and seroto-
nin-specific reuptake inhibitors have been approved for
treating FM pain by the United States Food and Drug
Administration. As the antinociceptive activities of these
compounds are largely independent of their effects on
mood, making them potentially efficacious for patients
with or without depressive [37], it appears to reflect the
Table 2 Permanent relief from ICS-induced thermal hyperalgesia by repeated intrathecal (i.t.) administration of











8 9.84 ± 0.33 9.81 ± 0.45 10.24 ± 0.23 9.99 ± 0.22
ICS-vehicle
(i.t.)
8 10.22 ± 0.28 5.76 ± 0.15* 6.04 ± 0.16* 6.28 ± 0.21*
ICS- amitriptyline
(15 μg, i.t.)
4 10.48 ± 0.23 5.35 ± 0.36 8.44 ± 0.16# 9.35 ± 0.66#
ICS-mianserin
(20 μg, i.t.)
4 9.68 ± 0.30 5.35 ± 0.36 8.13 ± 0.25# 9.95 ± 0.66#
ICS- paroxetine
(5 μg, i.t.)
4 9.82 ± 0.44 5.47 ± 0.13 9.08 ± 0.46# 9.52 ± 0.21#
Antidepressants were administered between P1-P5, as described in Figure 3. Thermal pain threshold was assessed using the thermal paw withdrawal test. *p <
0.05, vs. vehicle-treated control group; #p < 0.05, vs. vehicle-treated and ICS-exposed groups.











8 9.51 ± 0.22 9.80 ± 0.18 10.00 ± 0.29 9.57 ± 0.30
ICS-vehicle
(i.v.)
8 9.67 ± 0.23 5.78 ± 0.36 6.02 ± 0.12 6.36 ± 0.21
ICS- amitriptyline
(3 mg/kg, i.v.)
4 9.55 ± 0.42 5.85 ± 0.37 5.79 ± 0.36 6.72 ± 0.35
ICS-mianserin
(10 mg/kg, i.v.)
4 9.77 ± 0.34 5.14 ± 0.56 5.98 ± 0.39 6.66 ± 0.41
ICS- paroxetine
(1 mg/kg, i.v.)
4 9.34 ± 0.36 5.29 ± 0.34 6.89 ± 0.30 6.96 ± 0.65
ICS- milnacipran
(10 mg/kg, i.v.)
4 9.75 ± 0.47 6.25 ± 0.25 6.71 ± 0.21 7.54 ± 0.53
Amitriptyline, mianserin, paroxetine or milnacipran were given intravenously (i.v.) and assessment of basal nociceptive thresholds was performed as described in
Figure 5. Thermal pain threshold was assessed using the thermal paw withdrawal test. *p < 0.05, vs. vehicle-treated control group.
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importance of central descending monoaminergic path-
ways in pain regulation [38,39]. Recent studies revealed
that polymorphisms in the 5-HT receptor, transporter,
and metabolic enzyme can contribute to the etiology of
FM [40-42]. The fMRI study also demonstrates that
brain regions involved in descending pain inhibitory
pathways appear to have decreased activity in FM
patients [43]. Although serotonergic and/or noradrener-
gic pathways are well documented as descending pain
inhibitory pathways [39], there is no report that the
abnormality of such descending monoaminergic systems
is observed in FM patients. However, it would be chal-
lenging to examine the effects of representative antide-
pressants on ICS-induced abnormal pain by introducing
the drugs into the intrathecal space, very close to target
regions.
Our study shows that the repeated intrathecal admin-
istration of different antidepressants gradually sup-
pressed ICS-induced pain. The gradual reversal of
abnormal pain may be related to the down-regulation of
b-adrenoceptors or abnormal monoaminergic metabo-
lism [44-46]. Alternative mechanisms may include the
altered expression of multiple receptors and ion chan-
nels, such as the NMDA receptor, opioid receptors, and
sodium channels [47-49]. It should be noted that the
reversal of abnormal pain continued after the cessation
of drug treatment, for each of the antidepressants tested.
Although further investigation is required to clarify the
molecular mechanisms of antidepressant action and to
provide a permanent cure for ICS-induced abnormal
pain, it is interesting to speculate that the chronic pain
may be due to a vicious cycle of pain elicited by reduced
inhibitory input from monoaminergic pathways. Thus,
the rescue of pain-inhibitory mechanisms by repeated
antidepressant treatment should halt chronic pain. Simi-
lar observations were made in our previous study using
central administration of gabapentin [13,14]. In that
study, using the ICS model, a single intracerebroventri-
cular administration of gabapentin produced a 4-day
period of anti-hyperalgesia. As the injection had no
effect on peripheral nerve injury-induced neuropathic
pain [13,14], and the gabapentin was unlikely to have
remained in the brain for 4 days, it is interesting to
speculate that the observed effect is due to the inhibi-
tion of the pain cycle, possibly through enhancement of
inhibitory transmission. However, the present study
demonstrates that systemic administration of various
antidepressants had no significant beneficial effect on
ICS-induced hyperalgesia, though they had a significant
acute analgesic effect in control mice. As the clinically
beneficial effects of oral antidepressants to FM patients
were evident when they are treated for more than sev-
eral weeks [50], the lack of effects of intravenous antide-
pressants in the present study may be attributed to the
shortage of treatments (5 days). In this meaning it is
surprising that only 5 days repetitive intrathecal treat-
ments abolishes abnormal pain even after the cession of
treatments. Furthermore, although the mechanisms
underlying the lack of antihyperalgesic effect remain elu-
sive, it may be worthwhile to investigate possible invol-
vements of interference of spinal effects by peripheral
pain facilitating serotonergic actions or by descending
pain facilitating monoaminergic systems [39]. Thus, we
expect that repetitive intrathecal administration of anti-
depressants are likely to be more effective at treating
FM-like pain in mouse models.
Finally, this study demonstrates that the ICS model has
similarities to clinical features of FM in terms of the sen-
sitivity to analgesics or adjuvant analgesics. In our pre-
vious findings, we observed that the effective dose of
gabapentin was 3 mg/kg for ICS-induced pain, but was
over 30 mg/kg for nerve injury-induced neuropathic pain
in mice [13,14], consistent with the fact that the clini-
cally-effective dose of gabapentin for FM patients is
lower than that for neuropathic pain [51]. In addition, we
observed that ICS-induced thermal hyperalgesia was
resistant to morphine treatment [13,14], consistent with
the clinical evidence [52]. Considering that other experi-
mental animal models of FM-like pain exhibit morphine
analgesia (albeit with low potency) [53-56], the ICS
model may be pharmacologically distinct from the others.
6. Conclusion
This study demonstrates that repeated intrathecal anti-
depressant treatment provides a complete cure of ICS-
induced FM-like abnormal pain. Based on the pharma-
cological similarity of ICS-induced pain to clinical FM,
the ICS model appears to be suitable for investigating
the pathogenesis of FM and for evaluating therapeutic
strategies for this debilitating illness.
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